Does anti-tumour necrosis factor treatment modify the tuberculin PPD response?

Anti-tumour necrosis factor (anti-TNF) in the treatment of juvenile idiopathic arthritis-associated uveitis

Results Of the 16 patients, 10 were treated with etanercept (62.5%), 1 with adalimumab (6.25%), and 5 (31.2%) with infliximab. Notably, two cases of uveitis were associated with use of etanercept. In 5 patients (31.2%) the antiTNF was changed because of lack of efficacy and/or side effects to another one (in 4/5 adalimumab). Ten patients had a complicated uveitis (cataract in 5). The number of ...

Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis.

Preclinical studies based on in vitro cell systems and in vivo models had established a position for tumour necrosis factor (TNF) á as a pivotal molecule regulating cellular activation and interactions in rheumatoid inflammation by 1992. That neutralisation of TNFá has a profound impact on the biology of inflammation is reflected by the rapid reduction in the concentration of C reactive protein...

Anti-Tumour Necrosis Factor-α Induced Systemic Lupus Erythematosus

Mycobacterial diseases developed during anti-tumour necrosis factor-α therapy.

Nontuberculous mycobacterial (NTM) disease and tuberculosis (TB) develop during anti-tumour necrosis factor (TNF)-α therapy. We compared clinical characteristics and outcomes between the two diseases. A total of 1165 patients were screened for TB and treated with TNF-α antagonists from July 2004 to July 2013 for the following conditions: inflammatory bowel disease (n = 422), rheumatoid arthriti...

Anti-Tumour Necrosis Factor-α Therapy in Crohn’s Disease

Crohn’s disease is a chronic, relapsing, inflammatory disease of the gastro-intestinal tract. Manifestations of the disease may be severe, and lead to long-term therapy with a variety of medications and/or surgery. There are two main classifications of the disease, including the relapsing-remitting chronic active variety, and the penetrating or fistulising variety. Tumour necrosis factor-alpha ...